GlycoMimetics
-
Let data – not politics – guide development of Covid-19 drugs, vaccines, biotech execs urge
In an open letter published by BIO, the executives emphasized the importance of science-driven evaluation of medicines and regulatory independence. The letter came amid growing concern about political pressure over the FDA, as well as lack of diversity in trials and companies being too quick to announce data that are inconclusive.
-
GlycoMimetics’ shares plunge as Phase III sickle cell disease trial fails
Pfizer, which had been running the trial of rivipansel in SCD, reported that it had failed on its primary and key secondary endpoints.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.